γδ T cells as a potential tool in colon cancer immunotherapy.

abstract：AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

journal_title：Immunotherapy

authors： Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

更新日期：2014-01-01 00:00:00

abstract：:Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...

journal_title：Immunotherapy

authors： Shek D,Read SA,Akhuba L,Qiao L,Gao B,Nagrial A,Carlino MS,Ahlenstiel G

更新日期：2020-05-01 00:00:00

abstract：:Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2014-01-01 00:00:00

abstract：AIM:To assess carnitine serum levels and possible risk factors of its deficiency in patients with TB. PATIENTS & METHODS:All newly diagnosed TB patients admitted to an infectious diseases ward were recruited. Demographic, clinical and paraclinical characteristics of the patients were collected. Total carnitine serum c...

journal_title：Immunotherapy

authors： Hatamkhani S,Khalili H,Karimzadeh I,Abdollahi A,Jafari S,Khazaeipour Z

更新日期：2013-09-01 00:00:00

abstract：AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

journal_title：Immunotherapy

authors： Liu T,Xiong Q,Li L,Hu Y

更新日期：2019-04-01 00:00:00

abstract：:Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

journal_title：Immunotherapy

authors： Pegram HJ,Kershaw MH,Darcy PK

更新日期：2009-07-01 00:00:00

abstract：:Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

journal_title：Immunotherapy

authors： Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

更新日期：2014-01-01 00:00:00

abstract：:Aim: To investigate whether and how CD4+ T cells contribute to ILC2 activation during respiratory syncytial virus (RSV) infection. Methods: The methods of flow cytometry, quantitative PCR and ELISA were used in the present study. Results: Depletion of CD4+ T cells diminished the numbers of lung ILC2s as well as their ...

journal_title：Immunotherapy

authors： Han X,Bai S,Cui Y,Zhu W,Zhao N,Liu B

更新日期：2019-10-01 00:00:00

abstract：:The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2011-08-01 00:00:00

abstract：:Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

journal_title：Immunotherapy

authors： Mahmoud AM

更新日期：2018-07-01 00:00:00

abstract：AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

journal_title：Immunotherapy

authors： Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

更新日期：2012-12-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

journal_title：Immunotherapy

authors： Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

更新日期：2021-02-01 00:00:00

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...

journal_title：Immunotherapy

authors： Ott PA,Adams S

更新日期：2011-02-01 00:00:00

abstract：:Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkabl...

journal_title：Immunotherapy

authors： Janakiram M,Pareek V,Cheng H,Narasimhulu DM,Zang X

更新日期：2016-06-01 00:00:00

abstract：:Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

journal_title：Immunotherapy

authors： Huang J,Rong L,Wang E,Fang Y

更新日期：2021-01-01 00:00:00

abstract：:Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

journal_title：Immunotherapy

authors： El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

更新日期：2020-12-01 00:00:00

abstract：:There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

journal_title：Immunotherapy

authors： Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

更新日期：2012-08-01 00:00:00

abstract：:In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

journal_title：Immunotherapy

authors： Vonka V

更新日期：2010-03-01 00:00:00

abstract：:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

journal_title：Immunotherapy

authors： Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

更新日期：2014-01-01 00:00:00

abstract：:Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

journal_title：Immunotherapy

authors： Shaffer DR,Rooney CM,Gottschalk S

更新日期：2010-09-01 00:00:00

abstract：:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

journal_title：Immunotherapy

authors： Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

更新日期：2015-01-01 00:00:00

abstract：AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

journal_title：Immunotherapy

authors： Pružinec P,Chirun N,Sveikata A

更新日期：2018-02-01 00:00:00

abstract：:Osteoarthritis is a disabling disease of the aging generation, which results in loss of quality of life and increased healthcare costs. Cytokines appear to play an important role in the cartilaginous degeneration characterizing the pathological process. Increasing experience is being gained with cytokine-modulating th...

journal_title：Immunotherapy

authors： Rutgers M,Saris DB,Yang KG,Dhert WJ,Creemers LB

更新日期：2009-05-01 00:00:00

abstract：:NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

journal_title：Immunotherapy

authors： Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

更新日期：2011-10-01 00:00:00

abstract：:Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

journal_title：Immunotherapy

authors： van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

更新日期：2010-01-01 00:00:00

abstract：:Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into tw...

journal_title：Immunotherapy

authors： Prasanna T,Arasaratnam M,Boyer M,McNeil C,Barnet MB,Asher R,Hui R,Nagrial A,Kao S

更新日期：2019-06-01 00:00:00

abstract：:Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...

journal_title：Immunotherapy

authors： Pinelli DF,Ford ML

更新日期：2015-01-01 00:00:00

abstract：:Cancer-testis (CT) antigens are tumor-associated antigens attracting immunologists for their possible application in the immunotherapy of cancer. Several clinical trials have assessed their therapeutic potentials in cancer patients. Breast cancers, especially triple-negative cancers are among those with significant ex...

journal_title：Immunotherapy

authors： Ghafouri-Fard S,Shamsi R,Seifi-Alan M,Javaheri M,Tabarestani S

更新日期：2014-01-01 00:00:00